Quest Diagnostics Incorporated (DGX)

Quest Diagnostics' stock has been influenced by several events over the past six months. The company reported better-than-expected Q2 2025 earnings, with revenue up 15.2% year-on-year, but the stock declined due to investor concerns. Following its Q2 performance, the company raised its full-year 2025 revenue and adjusted EPS guidance. In late September 2025, DGX stock reached a new 52-week high. Quest Diagnostics declared a quarterly dividend of $0.80 per share. Some analysts lowered their target prices and downgraded ratings for DGX between July and August 2025.

While some specific diagnostic tests may experience increased demand during flu season, the overall demand for Quest Diagnostics' services is primarily driven by consistent, long-term healthcare trends. Key drivers include the rising prevalence of chronic diseases, an aging global population, and an increase in awareness and need for early disease detection and personalized care. The company also offers seasonal promotions and discounts on select tests.

Quest Diagnostics, Inc. (DGX) is a leading provider of diagnostic information services in the healthcare industry, offering a broad spectrum of diagnostic testing, information, and services to various stakeholders. The company operates within the Healthcare sector, focusing on Diagnostics & Research and Healthcare Providers and Services industries, providing routine clinical testing, genetic and molecular testing, infectious disease testing, drug-of-abuse screening, anatomic pathology testing, risk assessment services, and healthcare information technology solutions.

Quest Diagnostics has a significant geographic presence across the United States, Puerto Rico, Mexico, and Brazil. It maintains an extensive network of approximately 2,300 patient service centers in the U.S. and engages in collaborative agreements with various hospitals and clinics globally.

Quest Diagnostics maintains a strong brand reputation and was named one of FORTUNE's "World's Most Admired Companies" in 2024 for the tenth consecutive year. This recognition is based on criteria such as innovation, quality of management and products, social responsibility, and people management.

Quest Diagnostics has a widely held ownership structure, with a significant portion held by institutional investors including Vanguard Group Inc, BlackRock, Inc., and others. Institutional investors collectively hold a substantial percentage of the company's stock, ranging from approximately 75.58% to 92.72%, while individual investors hold a relatively smaller portion.